Harris v. Ivax Corp.

998 F. Supp. 1449, 1998 U.S. Dist. LEXIS 6930
CourtDistrict Court, S.D. Florida
DecidedMarch 30, 1998
Docket97-0559-CIV
StatusPublished
Cited by12 cases

This text of 998 F. Supp. 1449 (Harris v. Ivax Corp.) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Harris v. Ivax Corp., 998 F. Supp. 1449, 1998 U.S. Dist. LEXIS 6930 (S.D. Fla. 1998).

Opinion

ORDER GRANTING DEFENDANTS’ MOTION TO DISMISS

MORENO, District Judge.

This is a securities fraud class action suit brought against IVAX corporation and two of its officers by a class of Plaintiffs who purchased IVAX common stock between August 2, 1996 and November 11, 1996. Plaintiffs allege that they were fraudulently induced to make these purchases by the materially false and misleading statements and omissions made by the Defendants. The issue before the Court is whether Defendants’ statements fall within the safe harbor provision of the Private Securities Litigation Reform Act of 1995 (“Reform Act”). Because the Court finds that the Defendants’ statements were forward-looking statements accompanied by meaningful cautionary language qualifying for the safe harbor’s protection, the Court grants Defendants’ motion to dismiss.

Relevant Background

IVAX is pharmaceutical company headquartered in Miami, Florida. • One of its primary lines of business is the manufacture of generic drugs, a business that has proved in recent years to be highly volatile. Although highly profitable in its early years, beginning in the second quarter of 1996, IVAX began to suffer a serious decline in earnings. IVAX reported a loss from operations that quarter of $13.9 million, or $0.11 a share, compared with net income of $28.1 million, or $0.24 per share a year earlier. The loss was attributed to reduced margins, lower prices, higher than anticipated levels of customer inventory credits, and the establishment of additional reserves for customer inventory returns.

In a press release issued August 2, 1996, the first day of the Class Period, Defendant Frost, the Chairman and Chief Executive Officer of IVAX stated:

Clearly, we have experienced a very disappointing quarter. We believe, however, that the challenges unique to this period in our history are now behind us. The broader challenges of the generic drug industry as a whole, and its tremendous opportunities, remain. We will meet these challenges with strategies honed and improved as a result of this most difficult quarter. More significantly, we will continue to exploit the industry’s opportunities with a science team that has led the industry in U.S. generic drug approvals, and with a distribution network that is among the most extensive in the industry.
In evaluating our strategies, we have taken a hard look at oür U .S. generic drug business. We have determined that, although we will not be blind to opportunities outside our organization to improve shareholder value, we must focus our resources on improving value from within. We have instituted actions to enhance the profitability of our U.S. generic business. We will also be expanding our management team and consolidating manufacturing facilities.
In addition, we have begun to moderate those selling initiatives in our U.S. generics business which can create high levels of inventory in the distribution channels, and to develop a base' óf long term customer contracts and arrangements. We believe this will permit us to distribute sales more evenly over the quarter and, accordingly, reduce heavy end-of-quarter selling.
Our fundamental business and its underlying strategies remain intact: the U.S. market for generic drugs doubled over the last three years to more than $6 billion, and industry experts generally expect it to double yet again over the next three to five years. Only a limited number of companies are positioned to meaningfully participate in this rapidly growing market and, among them, IVAX is certainly very well positioned.

Notably, the end of the August 2, 1996 press release contained the following warning in italic print:

Statements made in this press release, including those relating to expectations of increased reorders, receipt of a credit facility waiver, earnings distribution, and the generic drug industry, are forward *1451 looking and are made pursuant to the safe harbor provisions of the Securities Reform Act of 1995. Such statements involve risks and uncertainties which may cause results to differ materially from those set forth in those statements. Among other things, additional competition from, existing and new competitors mil impact reorders; the credit facility waiver is subject to the discretion of the bank syndicate; and IVAX’s ability to distribute earnings more evenly over future quarters is subject to industry practices and purchasing decisions by existing and potential customers. In addition, the U.S. generic drug industry is highly price competitive, with pricing determined by many factors, including the number and timing of product introductions. Although the price of generic product generally declines over time as competitors introduce additional versions of the product, the actual degree and timing of price competition is not predictable. In addition to the factors set forth in this release, the economic, competitive, governmental, technological and other factors identified in WAX’s filing with the Securities and Exchange Commission, could affect the forward looking statements contained in this press release.

On September 30, 1996, the last day of the third fiscal quarter, IVAX announced a $13 million restructuring program, which it stated would reduce costs by $20 million a year. In addition to the restructuring, the September 30,1996 press release stated:

[Sjeveral factors relating to our U.S. generic drug business will influence our third quarter results. First, our customer inventory levels continue to be high, so customer re-orders remain depressed. Second, prices have continued to decline for generic drug products. Third, lower prices at a time of elevated inventories will increase shelf stock adjustments paid to customers to levels well above more typical quarters. Fourth, we expect reserves for returns and inventory writeoffs to be well above typical quarters as well. Lastly, a wholesaler customer who owed us approximately $16 million filed a Chapter 11 bankruptcy proceeding during the third quarter. Accordingly, in the 1996 third quarter, we supplemented our existing second quarter reserves of approximately $6 million relating to this account with additional reserves of approximately $7 million.

The Defendants represented that IVAX would suffer a total third quarter loss of $43 million. The press release, however, quoted Defendant Frost as stating: “Because certain of the factors affecting the quarter are subject to estimation and cannot be precisely quantified at this time, the actual loss for the quarter ultimately may be greater or less than our forecasted loss by as much as several million dollars.” In addition, the September 30, 1998 press release included an italicized warning:

Statements made in this press release, including ... the expected loss for the third quarter ... are forward looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re KLX, Inc. Securities Litigation
232 F. Supp. 3d 1269 (S.D. Florida, 2017)
Plymouth County Retirement Ass'n v. Primo Water Corp.
966 F. Supp. 2d 525 (M.D. North Carolina, 2013)
In Re Scientific Atlanta, Inc. Securities Litigation
754 F. Supp. 2d 1339 (N.D. Georgia, 2010)
In Re Synchronoss Securities Litigation
705 F. Supp. 2d 367 (D. New Jersey, 2010)
Edward J. Goodman Life Income Trust v. Jabil Circuit, Inc.
560 F. Supp. 2d 1221 (M.D. Florida, 2008)
Lesavoy v. Lane
304 F. Supp. 2d 520 (S.D. New York, 2004)
Harris v. Ivax Corporation
182 F.3d 799 (Eleventh Circuit, 1999)
Karacand v. Edwards
53 F. Supp. 2d 1236 (D. Utah, 1999)
Rhodes v. Omega Research, Inc.
38 F. Supp. 2d 1353 (S.D. Florida, 1999)
In Re Boeing Securities Litigation
40 F. Supp. 2d 1160 (W.D. Washington, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
998 F. Supp. 1449, 1998 U.S. Dist. LEXIS 6930, Counsel Stack Legal Research, https://law.counselstack.com/opinion/harris-v-ivax-corp-flsd-1998.